Kidney transplant and its outcomes: Five-year single-center experience from Central India

R. Banode, P. Kimmatkar, C. Bawankule, Vandana Adamane
{"title":"Kidney transplant and its outcomes: Five-year single-center experience from Central India","authors":"R. Banode, P. Kimmatkar, C. Bawankule, Vandana Adamane","doi":"10.4103/jcrsm.jcrsm_61_21","DOIUrl":null,"url":null,"abstract":"Background: Kidney transplantation has become the treatment of choice for most patients with end-stage kidney disease (ESKD). However, there is a remarkable disparity in the access and outcome of kidney transplant across the world. We present the clinical and survival data from the nephrology and kidney transplantation center for a period of 5 years in a cost-limited setting from Central India. Materials and Methods: This is a retrospective study of 66 kidney transplants performed in a single transplant center over a period of 5 years from 2016 to 2020. All data of recipients and donors were obtained from hospital records. Kaplan–Meier method was used for survival analysis. Results: Of 66 included patients, 86% were living donor and 14% were cadaveric kidney transplant. The mean age of the recipient was 30.64 ± 10.66 years. Fifty-five (83%) were male recipients and 11 (17%) were female recipients. The most common cause of ESKD in recipients was chronic glomerulonephritis (55%). The mean hemodialysis vintage was 11.04 ± 10.12 months. Seventy-four percent of donors were female and 24% of donors were male. Induction therapy with rabbit antithymocyte globulin was used in 20 (30%) and basiliximab in 21 (32%) recipients. Thirty (45%) recipients underwent graft kidney biopsy in view graft dysfunction. Acute cellular rejection was the most common cause of graft dysfunction seen in 8 (28%) of graft kidney biopsy. Graft survival and patient survival at 1, 3, and 5 years after transplant were 89%, 81%, and 77% and 90%, 84%, and 81%, respectively. Conclusions: Our observation showed that graft survival and patient survival after transplant were lower compared to other studies due to higher rejection rate and mortality due to infections. Hence, attention to immunological risk factors with proper immunologic testing pretransplant and early detection and adequate treatment of rejection episode even in cost-limited settings are suggested. Also after kidney transplant, prevention and prompt treatment of infection would offer the greatest potential to improve the chance of living longer with functioning graft.","PeriodicalId":32638,"journal":{"name":"Journal of Current Research in Scientific Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Research in Scientific Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrsm.jcrsm_61_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Kidney transplantation has become the treatment of choice for most patients with end-stage kidney disease (ESKD). However, there is a remarkable disparity in the access and outcome of kidney transplant across the world. We present the clinical and survival data from the nephrology and kidney transplantation center for a period of 5 years in a cost-limited setting from Central India. Materials and Methods: This is a retrospective study of 66 kidney transplants performed in a single transplant center over a period of 5 years from 2016 to 2020. All data of recipients and donors were obtained from hospital records. Kaplan–Meier method was used for survival analysis. Results: Of 66 included patients, 86% were living donor and 14% were cadaveric kidney transplant. The mean age of the recipient was 30.64 ± 10.66 years. Fifty-five (83%) were male recipients and 11 (17%) were female recipients. The most common cause of ESKD in recipients was chronic glomerulonephritis (55%). The mean hemodialysis vintage was 11.04 ± 10.12 months. Seventy-four percent of donors were female and 24% of donors were male. Induction therapy with rabbit antithymocyte globulin was used in 20 (30%) and basiliximab in 21 (32%) recipients. Thirty (45%) recipients underwent graft kidney biopsy in view graft dysfunction. Acute cellular rejection was the most common cause of graft dysfunction seen in 8 (28%) of graft kidney biopsy. Graft survival and patient survival at 1, 3, and 5 years after transplant were 89%, 81%, and 77% and 90%, 84%, and 81%, respectively. Conclusions: Our observation showed that graft survival and patient survival after transplant were lower compared to other studies due to higher rejection rate and mortality due to infections. Hence, attention to immunological risk factors with proper immunologic testing pretransplant and early detection and adequate treatment of rejection episode even in cost-limited settings are suggested. Also after kidney transplant, prevention and prompt treatment of infection would offer the greatest potential to improve the chance of living longer with functioning graft.
肾移植及其结果:来自印度中部的五年单中心经验
背景:肾移植已成为大多数终末期肾病(ESKD)患者的治疗选择。然而,世界各地在肾脏移植的可及性和结果上存在着显著的差异。我们介绍了在印度中部一个费用有限的环境中,肾脏学和肾移植中心5年的临床和生存数据。材料与方法:本研究回顾性分析了2016年至2020年5年间在单一移植中心进行的66例肾移植手术。所有受体和供体数据均来自医院记录。采用Kaplan-Meier法进行生存分析。结果:66例患者中,86%为活体肾供体,14%为尸体肾移植。患者平均年龄30.64±10.66岁。55名(83%)男性接受者,11名(17%)女性接受者。受体中最常见的ESKD病因是慢性肾小球肾炎(55%)。平均血液透析时间为11.04±10.12个月。74%的献血者是女性,24%的献血者是男性。20例(30%)接受兔抗胸腺细胞球蛋白诱导治疗,21例(32%)接受basiliximab诱导治疗。30例(45%)受者因移植物功能障碍接受肾活检。急性细胞排斥反应是8例(28%)移植肾活检中最常见的移植物功能障碍原因。移植后1年、3年和5年的移植物生存率和患者生存率分别为89%、81%、77%和90%、84%、81%。结论:我们的观察显示,与其他研究相比,由于较高的排斥率和感染死亡率,移植物存活率和移植后患者存活率较低。因此,建议注意免疫危险因素,在移植前进行适当的免疫检测,及早发现和适当治疗排斥反应,即使在费用有限的情况下也是如此。此外,在肾移植后,预防和及时治疗感染将提供最大的潜力,以提高活得更久的机会与功能移植。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
13
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信